Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 13/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7559963 | 0.85 | RYR2 (0.63) | RYR2MEN1KMT2ANOTUM | |
| SCHEMBL7558332 | 0.84 | RYR2 (0.53) | RYR2KMT2ANOTUM | |
| SCHEMBL13387456 | 0.81 | RYR2 (0.48) | RYR2MEN1KMT2ANOTUMTSHR | |
| SCHEMBL13622077 | 0.79 | RYR2 (0.52) | RYR2L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL6241042 | 0.73 | KMT2A (0.50) | CYP1A2CYP2D6CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL8117456 | 0.73 | KMT2A (0.50) | CYP1A2CYP2D6CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL3007964 | 0.73 | KMT2A (0.66) | CYP1A2CYP2D6CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL7559424 | 0.72 | RYR2 (0.55) | RYR2NOTUM | |
| SCHEMBL9635059 | 0.72 | RYR2 (0.72) | RYR2NOTUM | |
| SCHEMBL8248175 | 0.72 | RYR2 (0.57) | RYR2CYP2D6CYP2C19NOTUMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292119-A1 | METHODS FOR SYNTHESIZING BENZOTHIAZEPINE COMPOUNDS | KCNB2, KCNJ2, KCNJ5 | RYR2 275/4885CYP1A2 130/4885CYP2D6 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.